Compare Inovio Pharmaceuticals Inc (INO) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Warner Music Group Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $1.12 (market cap $112.19M), while Warner Music Group Corp trades at $28.86 (market cap $15.12B). The key difference: Warner Music Group Corp is far larger — about 134.8× Inovio Pharmaceuticals Inc's market cap, and Warner Music Group Corp pays a 2.77% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Warner Music Group Corp for 96 Days on average.
| INO | WMG | |
|---|---|---|
Market Cap | $112.19M | $15.12B |
Volume | 3,201,278 | 2,966,414 |
Sector | Health | Media |
52-Week High | $2.65 | $34.72 |
52-Week Low | $0.66 | $23.65 |
Typical Hold Time | 43 Days | 96 Days |
Enterprise Value | $83.51M | $19.42B |
Dividend Yield | — | 2.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
WMG trades at $28.875, up 2.54% today, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $0.38, beating expectations, and has a strong analyst consensus of 'Buy' with a $39.50 price target. Recent news highlights AI partnerships and licensing renewals as growth catalysts.
Outlook remains positive due to streaming growth and AI initiatives, but risks include competitive pressures and margin volatility. The stock offers upside potential from current levels if execution continues, though investor caution is warranted near-term given elevated RSI levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
